A Phase II Study to Evaluate the Effects of Cabozantinib in Patients With Unresectable/Metastatic Adrenocortical Carcinoma
Latest Information Update: 23 Jan 2024
At a glance
- Drugs Cabozantinib (Primary)
- Indications Adrenocortical carcinoma
- Focus Therapeutic Use
- 17 Jan 2024 Status changed from active, no longer recruiting to completed.
- 13 Sep 2022 Results presented at the 47th European Society for Medical Oncology Congress
- 29 Apr 2022 Planned End Date changed from 28 Feb 2022 to 28 Feb 2026.